BDSX BDSX
Company Profile ↓Company Overview
BDSX (BDSX) is a publicly traded company listed on with a market capitalization of $188.00M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 23.8% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $88.50M (+24.1% YoY); net profit $-35.27M.
- Trailing 12 Months Year-on-year growth — revenue +24.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 23.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 23.83% |
| 1 Year: | 24.08% |
Stock Price Performance
| 1 Year: | +196.61% |
| 6 Months: | +106.53% |
| 3 Months: | +52.48% |
| 1 Month: | +12.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.65 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 23.8% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 3.94M | 5.10M | 4.24M | 9.19M | 28.87M | 11.88M | 6.53M | 6.55M | 10.95M | 11.11M | 9.06M | 11.87M | 13.49M | 14.82M | 17.93M | 18.15M | 17.96M | 20.02M | 21.77M | 25.55M |
| Operating Income | - | - | -9.03M | -8.42M | -5.62M | -6.24M | -5.58M | -10.59M | -13.09M | -14.46M | -11.63M | -10.61M | -16.37M | -10.93M | -7.17M | -11.02M | -8.24M | -8.59M | -9.14M | -9.72M | -7.05M | -6.20M |
| Net Income | -7.74M | -6.86M | -9.60M | -9.71M | -8.27M | -8.85M | -6.96M | -11.40M | -11.51M | -15.59M | -15.82M | -13.70M | -18.70M | -13.36M | -10.95M | -13.61M | -10.81M | -10.26M | -11.10M | -11.47M | -8.72M | -7.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.41 | -0.50 | -0.40 | -0.34 | -0.24 | -0.17 | -0.14 | -0.14 | -0.08 | -1.40 | -1.52 | -0.08 | -1.16 | -0.81 |
| R&D Expense | - | - | 2.36M | 2.90M | 2.11M | 2.71M | 3.32M | 3.32M | 3.29M | 3.21M | 3.36M | 2.97M | 3.25M | 2.91M | 1.94M | 2.04M | 2.56M | 2.55M | 2.87M | 3.27M | 2.99M | 3.29M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 24.55M | 45.56M | 54.51M | 38.21M | 49.09M | 71.32M | 88.50M |
| Operating Income | -26.74M | -22.93M | -40.94M | -50.59M | -41.34M | -34.50M | -27.87M |
| Net Income | -30.73M | -65.45M | -43.16M | -65.45M | -52.15M | -42.93M | -35.27M |
| Diluted EPS | - | - | -1.58 | -1.55 | -0.64 | -6.64 | -4.67 |
| R&D Expense | 10.47M | 10.82M | 12.79M | 13.10M | 9.99M | 9.56M | 12.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 45.03M | 121.07M | 76.10M | 92.91M | 99.10M | 97.24M | 87.48M |
| Current Assets | - | - | - | - | 53.33M | 39.68M | 39.48M | 32.52M |
| Cash & Equivalents | - | 5.29M | 62.13M | 32.71M | 43.09M | 26.28M | 26.25M | 18.99M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 5.07M | 7.68M | 8.60M | 9.04M |
| Total Liabilities | - | 76.21M | 79.90M | 56.37M | 72.30M | 94.52M | 76.37M | 89.94M |
| Current Liabilities | - | 22.60M | 32.12M | 28.96M | 22.84M | 33.42M | 14.32M | 17.44M |
| Long Term Debt | - | - | 28.08M | 10.07M | 25.00M | 35.23M | 36.41M | 47.45M |
| Total Debt | - | - | - | - | 31.85M | 60.69M | 61.98M | 72.85M |
| Total Equity | -194.63M | -225.14M | 41.17M | 19.73M | 20.61M | 4.58M | 20.88M | -2.46M |
| Shares Outstanding | - | - | - | - | 3.88M | 4.81M | 7.27M | 8.25M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.73M | -21.37M | -28.22M | -44.97M | -22.87M | -48.65M | -23.27M |
| Investing Cash Flow | -1.87M | -2.93M | -2.55M | -3.53M | -23.06M | -3.44M | -403.00K |
| Financing Cash Flow | 22.97M | 81.13M | 1.26M | 58.88M | 29.13M | 52.05M | 16.42M |
| Capital Expenditure | -1.31M | -1.95M | -2.24M | -3.30M | -22.92M | -3.23M | -259.00K |
| Free Cash Flow | -23.04M | -23.31M | -30.46M | -48.27M | -45.79M | -51.88M | -23.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | -108.9% | -50.3% | -75.1% | -132.4% | -84.2% | -48.4% | -31.5% |
| Net Margin % | -125.1% | -143.7% | -79.2% | -171.3% | -106.2% | -60.2% | -39.8% |
| ROE % | 13.6% | -159.0% | -218.8% | -317.6% | -1,138.6% | -205.6% | 1,430.6% |
| ROCE % | -119.2% | -25.8% | -86.9% | -72.2% | -62.9% | -41.6% | -39.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BDSX
Biodesix Q2 Earnings Call Highlights
Biodesix (NASDAQ:BDSX) reported second-quarter 2026 revenue growth of 34% year over year, supported by increased diagnostic test volumes, higher average revenue per test and continued expansion of its commercial organization. Total revenue …
Biodesix, Inc. (BDSX) Reports Q2 Loss, Beats Revenue Estimates
Biodesix (BDSX) delivered earnings and revenue surprises of +17.44% and +2.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Biodesix Announces Second Quarter 2026 Results and Highlights
Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 …
Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
LOUISVILLE, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will present in a fireside chat and host in-person 1x1…
BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?
bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in.
Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2026 after the close of…
BDSX — Frequently Asked Questions
What is the current share price of BDSX?
As of 2026-08-05 17:25 PDT, BDSX trades at $22.78 on NASDAQ/NYSE. Its 52-week range is $5.46 to $24.50.
What is the market capitalisation of BDSX?
BDSX has a market capitalisation of $188.00M on NASDAQ/NYSE.
What is the P/E ratio of BDSX?
BDSX trades at a trailing price-to-earnings (P/E) ratio of -4.88. Its price-to-book (P/B) ratio is -76.26.
Is BDSX a good stock to buy?
This page provides a data-driven analysis of BDSX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.